Therapeutic thoracocentesis in malignant pleural effusion

Comparison of 1 liter versus 1.5 liter therapeutic thoracocentesis, in symptomatic malignant pleural effusion

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014120120024N1

Enrollment

Registered

2015-01-05

Start date

2014-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant pleural effusion. Pleural effusion in conditions classified elsewhere

Interventions

Intervention 1: One liter Therapeutic Thoracentesis after topical anesthesia and sterilization by posterior inter-costal approach. Intervention 2: One and a half liter Therapeutic Thoracentesis after

Treatment - Other

One liter Therapeutic Thoracentesis after topical anesthesia and sterilization by posterior inter-costal approach

One and a half liter Therapeutic Thoracentesis after topical anesthesia and sterilization by posterior inter-costal approach

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Known malignancy (documented by cytology or pleural biopsy) ; 2. Moderate to severe dyspnea (requiring therapeutic thoracocentesis); 3. Malignant pleural effusion is the most possible cause of symptoms; 4. Awake and cooperative patients; 5. Moderate to severe pleural effusion on thoracic Computed tomography scan (more than 3 cm in anterior-posterior of thoracic cage); Exclusion criteria: 1.Age less than 18 2. Uncooperative patient; 3. Toxic patients with unstable hemodynamics and or Severe distress; 4. Intubated patients; 5. Chest tube insertion; 6. Bleeding diathesis; 7. Severe ascitis; 8. Impaired mental status; 9. Decompensated cardiac/renal/hepatic failure.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lung volumes. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: COSMED spirometer.;Severity of Dyspnea. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: Modified Borg Dyspnea Scale.;Functional quality of dyspnea. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: MRC breathlessness scale.;Arterial oxygen saturation of hemoglobin. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: Pulse oximeter.;Exercise Induced Oxygen Desaturatlon. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: 6 minute walk test.	—

Measure

Time frame

Lung volumes. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: COSMED spirometer.;Severity of Dyspnea. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: Modified Borg Dyspnea Scale.;Functional quality of dyspnea. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: MRC breathlessness scale.;Arterial oxygen saturation of hemoglobin. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: Pulse oximeter.;Exercise Induced Oxygen Desaturatlon. Timepoint: Just before the thoracocentesis and again within 24 hours after it. Method of measurement: 6 minute walk test.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: Discharge documents. Method of measurement: Days of admission.;Mortality within 28 days. Timepoint: 28 days after Thoracentesis. Method of measurement: Documents note and/or telephone follow up.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Soheil Peiman

Department of Internal medicine, Tehran university of medical sciences

s-peiman@tums.ac.ir; soheil_peiman@yahoo.com;+98 21 6693 9922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026